1. Home
  2. JPC vs SUPN Comparison

JPC vs SUPN Comparison

Compare JPC & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Preferred & Income Opportunities Fund

JPC

Nuveen Preferred & Income Opportunities Fund

HOLD

Current Price

$7.70

Market Cap

2.9B

Sector

Finance

ML Signal

HOLD

Logo Supernus Pharmaceuticals Inc.

SUPN

Supernus Pharmaceuticals Inc.

HOLD

Current Price

$46.20

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JPC
SUPN
Founded
N/A
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
2.8B
IPO Year
2003
2010

Fundamental Metrics

Financial Performance
Metric
JPC
SUPN
Price
$7.70
$46.20
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$61.60
AVG Volume (30 Days)
865.8K
854.3K
Earning Date
01-01-0001
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$392,755,000.00
Revenue This Year
N/A
$22.70
Revenue Next Year
N/A
$19.14
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.22
$32.83
52 Week High
$8.30
$59.68

Technical Indicators

Market Signals
Indicator
JPC
SUPN
Relative Strength Index (RSI) 33.68 45.67
Support Level $7.60 $43.43
Resistance Level $7.92 $46.79
Average True Range (ATR) 0.06 1.65
MACD -0.02 -0.16
Stochastic Oscillator 4.00 4.62

Price Performance

Historical Comparison
JPC
SUPN

About JPC Nuveen Preferred & Income Opportunities Fund

Nuveen Preferred & Income Opportunities Fund is a diversified closed-end management investment company. Its primary investment objective is to provide high current income, and its secondary investment objective is total return. The fund invests a majority of its assets in preferred securities and other income-producing securities, including hybrid securities such as contingent capital securities, and the rest of its investments are made in other securities, mainly income-oriented securities such as corporate and taxable municipal debt and common equity.

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.

Share on Social Networks: